Chikungunya virus infections - Pipeline Insight, 2021
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Chikungunya virus infections - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chikungunya virus infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Chikungunya virus infections: Overview
Chikungunya is a viral disease transmitted to humans through the bites of mosquitoes infected with the chikungunya virus. It was first described during an outbreak in southern Tanzania in 1952 and has now been identified in nearly 40 countries in Asia, Africa, Europe and, most recently, the Americas. Symptoms usually begin 4 to 8 days after a mosquito bite but can appear anywhere from 2 to 12 days. The most common symptom is an abrupt onset of fever, often accompanied by joint pain. Other symptoms include muscle pain, headache, nausea, fatigue, and rash. Severe joint pain usually lasts a few days but can persist for months or even years. Serious complications are uncommon, but atypical severe cases can cause long-term symptoms and even death, especially in older people.
'Chikungunya virus infections - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chikungunya virus infections pipeline landscape is provided which includes the disease overview and Chikungunya virus infections treatment guidelines. The assessment part of the report embraces, in depth Chikungunya virus infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chikungunya virus infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Chikungunya virus infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chikungunya virus infections Emerging Drugs
Further product details are provided in the report……..
Chikungunya virus infections: Therapeutic Assessment
This segment of the report provides insights about the different Chikungunya virus infections drugs segregated based on following parameters that define the scope of the report, such as:
Chikungunya virus infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chikungunya virus infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chikungunya virus infections drugs.
Chikungunya virus infections Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Chikungunya virus infections - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chikungunya virus infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Chikungunya virus infections: Overview
Chikungunya is a viral disease transmitted to humans through the bites of mosquitoes infected with the chikungunya virus. It was first described during an outbreak in southern Tanzania in 1952 and has now been identified in nearly 40 countries in Asia, Africa, Europe and, most recently, the Americas. Symptoms usually begin 4 to 8 days after a mosquito bite but can appear anywhere from 2 to 12 days. The most common symptom is an abrupt onset of fever, often accompanied by joint pain. Other symptoms include muscle pain, headache, nausea, fatigue, and rash. Severe joint pain usually lasts a few days but can persist for months or even years. Serious complications are uncommon, but atypical severe cases can cause long-term symptoms and even death, especially in older people.
'Chikungunya virus infections - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chikungunya virus infections pipeline landscape is provided which includes the disease overview and Chikungunya virus infections treatment guidelines. The assessment part of the report embraces, in depth Chikungunya virus infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chikungunya virus infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Chikungunya virus infections R&D. The therapies under development are focused on novel approaches to treat/improve Chikungunya virus infections.
This segment of the Chikungunya virus infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chikungunya virus infections Emerging Drugs
- VLA1553: Valneva
- mRNA-1944: Moderna Therapeutics
Further product details are provided in the report……..
Chikungunya virus infections: Therapeutic Assessment
This segment of the report provides insights about the different Chikungunya virus infections drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chikungunya virus infections
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Chikungunya virus infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chikungunya virus infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chikungunya virus infections drugs.
Chikungunya virus infections Report Insights
- Chikungunya virus infections Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chikungunya virus infections drugs?
- How many Chikungunya virus infections drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chikungunya virus infections?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chikungunya virus infections therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chikungunya virus infections and their status?
- What are the key designations that have been granted to the emerging drugs?
- Valneva
- Moderna Therapeutics
- Immunomodulation
- Ridgeback Biotherapeutics
- Etubics Corporation
- Themis Bioscience
- FIT Biotech
- Bharat Biotech
- Emergex Vaccines
- Emergent BioSolutions
- Indian Immunologicals Ltd.
- Auro Vaccines
- VLA1553
- mRNA 1944
- Annexin A5
- Molnupiravir
- MV-CHIK
- FIT-103
- BBV 87
- VRC CHKVLP059 00 VP
Introduction
Executive Summary
Chikungunya virus infections: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chikungunya virus infections – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
VLA1553: Valneva
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Chikungunya virus vaccine: Themis Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
mRNA 1944: Moderna Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
Research programme: chikungunya vaccine: Emergex Vaccines
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Chikungunya virus infections Key Companies
Chikungunya virus infections Key Products
Chikungunya virus infections- Unmet Needs
Chikungunya virus infections- Market Drivers and Barriers
Chikungunya virus infections- Future Perspectives and Conclusion
Chikungunya virus infections Analyst Views
Chikungunya virus infections Key Companies
Appendix
Executive Summary
Chikungunya virus infections: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chikungunya virus infections – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
VLA1553: Valneva
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Chikungunya virus vaccine: Themis Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
mRNA 1944: Moderna Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
Research programme: chikungunya vaccine: Emergex Vaccines
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Chikungunya virus infections Key Companies
Chikungunya virus infections Key Products
Chikungunya virus infections- Unmet Needs
Chikungunya virus infections- Market Drivers and Barriers
Chikungunya virus infections- Future Perspectives and Conclusion
Chikungunya virus infections Analyst Views
Chikungunya virus infections Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Chikungunya virus infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Chikungunya virus infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Chikungunya virus infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Chikungunya virus infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
